Premium Nahrungsergänzungsmittel | artgerecht

CTX – Bone Resorption Marker for Osteoporosis

CTX (C-terminal telopeptide of type I collagen) is a blood marker used to assess bone resorption. It plays a key role in diagnosing and monitoring osteoporosis.

Regular tips about health Regular tips about health

Things worth knowing about "CTX"

CTX (C-terminal telopeptide of type I collagen) is a blood marker used to assess bone resorption. It plays a key role in diagnosing and monitoring osteoporosis.

What is CTX?

CTX stands for C-terminal telopeptide of type I collagen. It is a small protein fragment released into the bloodstream and urine during the natural breakdown of bone tissue. CTX is one of the most clinically important bone resorption markers used in laboratory diagnostics today.

Biological Background

Bone is a dynamic tissue that is continuously broken down and rebuilt in a process known as bone remodeling. During bone resorption, specialized cells called osteoclasts release enzymes that degrade the collagen framework of the bone. This process generates fragments of type I collagen, including the C-terminal telopeptide (CTX). These fragments enter the bloodstream and are ultimately excreted through the kidneys in urine.

Forms of CTX

Serum CTX (Beta-CTX, β-CTX): The most widely used form in clinical diagnostics. The β-isomer is produced through a chemical modification (isomerization) of the collagen fragment and is highly specific for bone resorption.
Urinary CTX (CTX-I in urine): Less commonly measured, as serum values are more stable and easier to standardize.

When is CTX Measured?

CTX levels are measured in several clinical contexts:

Diagnosis and monitoring of osteoporosis: Elevated CTX values indicate increased bone resorption and may signal a higher risk of fracture.
Treatment monitoring: After initiating bone-protective therapy (e.g., with bisphosphonates), CTX levels typically decrease significantly, confirming treatment effectiveness.
Bone metastases monitoring: In cancer patients with bone involvement, CTX can reflect the extent of ongoing bone destruction.
Pre-dental procedure assessment: CTX is sometimes measured before dental implants or extractions to estimate the risk of osteonecrosis of the jaw in patients on bisphosphonate therapy.

Reference Values and Influencing Factors

Reference ranges for serum CTX vary by laboratory, sex, and age. Key factors affecting CTX levels include:

Time of day and food intake: CTX levels are highest in the morning after fasting and decline significantly after eating. Blood samples should therefore be collected in the morning under fasting conditions.
Menopausal status: After menopause, CTX levels in women often rise due to declining estrogen levels.
Age and sex: Values change throughout life and differ between men and women.
Kidney function: Impaired renal function can affect the clearance of CTX fragments from the body.

Clinical Significance

An elevated CTX level indicates increased bone resorption and may be associated with:

Osteoporosis
Paget's disease of bone
Hyperparathyroidism (overactive parathyroid glands)
Bone metastases
Hyperthyroidism (overactive thyroid gland)

A low CTX level may reflect a slowed bone metabolism. While this is desirable under antiresorptive therapy, excessively suppressed bone turnover may increase the risk of adynamic bone disease.

CTX Compared to Other Bone Markers

CTX belongs to the group of bone resorption markers. In contrast, bone formation markers such as procollagen type I N-propeptide (P1NP) or bone-specific alkaline phosphatase (BAP) assess the activity of bone-building cells (osteoblasts). Using both marker types together provides a comprehensive picture of overall bone metabolism.

References

Vasikaran S et al. – Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis International, 2011.
Dachverband Osteologie (DVO) – S3 Clinical Guideline on Osteoporosis, 2023. Available at: https://www.dv-osteologie.org
Eastell R et al. – Bone turnover markers in metabolic bone disease. Journal of Clinical Endocrinology & Metabolism, 2019.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.